https://european-biotechnology.net/wp-content/uploads/2026/03/matt-paul-catalano-0QEG_xOoY7Y-unsplash-1030x687-1.jpg6871030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-03-13 12:22:312026-03-13 12:22:31Owkin spins out AI diagnostics startup Waiv with $33M financing
https://european-biotechnology.net/wp-content/uploads/2026/03/freeze-frame-min-goldensite-valanx.jpg540960Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-03-12 16:09:502026-03-12 16:09:50Vienna’s VALANX secures €3 million to push preclinical ADC programme in breast cancer
https://european-biotechnology.net/wp-content/uploads/2026/03/moritz-mentges-XZuqMUiSdgc-unsplash-1030x688-1.jpg6881030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-03-12 13:00:112026-03-12 13:00:11Enodia strikes up to $127m deal for Kezar’s preclinical protein degradation assets
https://european-biotechnology.net/wp-content/uploads/2026/03/Evotec_HQ.jpeg540960Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-03-12 08:08:432026-03-12 08:08:43Hamburg CRO Evotec to cut costs further and reduce workforce by 800
https://european-biotechnology.net/wp-content/uploads/2026/03/getty-images-PGTMJ-rZOkQ-unsplash-1030x579-1.jpg5791030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-03-10 16:07:552026-03-10 16:07:55Ipsen withdraws cancer drug following safety concerns
https://european-biotechnology.net/wp-content/uploads/2025/09/BIONTECH-HQ_393139602_Zb0h3vxEfpoM8LCZnO6asKBbaVrnKYhj-e1757228010811.jpg5631000Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-03-10 11:24:502026-03-11 17:32:03A new departure: BioNTech’s founders step aside – Sahin and Türeci in new venture
https://european-biotechnology.net/wp-content/uploads/2026/01/roche-site-basel_official-web312708.jpeg540960Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-03-10 07:25:082026-03-10 07:25:08Roche breast cancer drug falls short of expectations (for now)
https://european-biotechnology.net/wp-content/uploads/2026/03/thought-catalog-fnztlIb52gU-unsplash-1030x687-1.jpg6871030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-03-09 16:48:362026-03-09 16:48:36Roche and Zealand’s obesity contender clears phase 2, but investors were looking for more
https://european-biotechnology.net/wp-content/uploads/2026/03/curated-lifestyle-FXxBAw-gcGU-unsplash-1030x678-1.jpg6781030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-03-09 15:23:462026-03-09 15:23:46Alfasigma bets up to $690M on GSK’s late-stage PBC itch drug ahead of FDA decision
https://european-biotechnology.net/wp-content/uploads/2026/03/eb-20260309-mohamed-nohassi-Jthv-V45G0E-unsplash-1030x579-1.jpg5791030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-03-09 14:10:552026-03-09 16:32:03Servier buys Day One for $2.5bn to bolster its rare cancer pipeline
